Alternate designs for conduct and analysis of phase I cancer trials [4] (multiple letters)

Blood

Volumn 98, Issue 4, 2001, Pages 1275-1276

  Lévy, Vincent ^a   Zohar, Sarah ^a   Porcher, Raphaël ^a   Chevret, Sylvie ^a   Gooley, Theodore ^a   Storer, Barry ^a   Press, Oliver W ^a  

^a SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; ETOPOSIDE; TOSITUMOMAB I 131;

AUTOTRANSPLANTATION; B CELL LYMPHOMA; BAYES THEOREM; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CLINICAL TRIAL; DOSE CALCULATION; DRUG INDUCED DISEASE; EMPIRICISM; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LETTER; MAXIMUM TOLERATED DOSE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE;

EID: 0035883054     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V98.4.1275     Document Type: Letter

References (0)